Sankyo halts CS-917 diabetes program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sankyo and partner Metabasis are halting development of their type 2 diabetes agent CS-917 following two cases of apparent lactic acidosis in a Phase II interaction study with metformin, Metabasis says March 16. Two trials have been halted and "a third study evaluating various doses of CS-917 administered as a single agent over three months is under review," the firm says. Metabasis maintains that the efficacy data for the gluconeogenesis/fructose bisphosphatase inhibitor are "promising"...